Kanuma® (Sebelipase Alfa) - CAM 962HB

Background

FDA-Approved Indication: Kanuma (sebelipase alfa) is a recombinant human lysosomal acid lipase (LAL) enzyme replacement therapy indicated for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D), including Wolman disease and Cholesteryl Ester Storage Disease (CESD).

Policy (Criteria)

Initial Authorization Criteria

Kanuma may be considered medically necessary when all of the following criteria are met:

1. Diagnosis of Lysosomal Acid Lipase Deficiency (LAL-D)

Including one of the following:

  • Wolman disease
  • Cholesteryl Ester Storage Disease (CESD)
  • Lysosomal Acid Lipase Deficiency (LAL-D)

2. Diagnosis confirmed by one of the following:

  • Enzymatic testing: Enzymatic blood test (e.g., dried blood spot assay) demonstrating deficient lysosomal acid lipase (LAL) enzyme activity
  • Genetic testing: Documentation of pathogenic mutation(s) in the LIPA (lipase A, lysosomal acid type) gene

3. Prescribed by or in consultation with one of the following:

  • Specialist experienced in the treatment of inherited metabolic disorders or inborn errors of metabolism
  • Gastroenterologist
  • Lipidologist

Authorization Duration: 6 months

Reauthorization Criteria

Kanuma may be reauthorized when all of the following criteria are met:

1. Documentation of positive clinical response to therapy to include one or more of the following:

  • Reduction in low-density lipoprotein cholesterol (LDL-C)
  • Reduction in triglyceride levels
  • Increase in high-density lipoprotein cholesterol (HDL-C)
  • Improvement or normalization of alanine aminotransferase (ALT)
  • Improvement or normalization of aspartate aminotransferase (AST)
  • Reduction in liver fat content
  • Reduction in hepatomegaly and/or splenomegaly
  • Improvement or stabilization of liver fibrosis
  • Improvement in growth parameters in pediatric patients
  • Improvement in disease-related symptoms and clinical status

2. Prescribed by or in consultation with one of the following:

  • Specialist experienced in the treatment of inherited metabolic disorders or inborn errors of metabolism
  • Gastroenterologist
  • Lipidologist

Authorization Duration: 12 months

References

  1. Kanuma® (sebelipase alfa) Prescribing Information. Alexion Pharmaceuticals, Inc. Current prescribing information.
  2. Burton BK, Balwani M, Feillet F, et al. A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency. New England Journal of Medicine. 2015;373:1010-1020.
  3. Jones SA, Valayannopoulos V, Schneider E, et al. Rapid Progression and Improved Survival with Sebelipase Alfa in Infants with Lysosomal Acid Lipase Deficiency. Molecular Genetics and Metabolism. 2016;118(2):113-119.
  4. Reiner Ž, Guardamagna O, Nair D, et al. Lysosomal Acid Lipase Deficiency: An Underrecognized Cause of Dyslipidemia and Liver Dysfunction. Atherosclerosis. 2014;235(1):21-30.
  5. American Association for the Study of Liver Diseases (AASLD). Guidance on evaluation and management of inherited metabolic liver diseases.
  6. National Organization for Rare Disorders (NORD). Lysosomal Acid Lipase Deficiency (LAL-D).
  7. GeneReviews®. Lysosomal Acid Lipase Deficiency.
  8. European Association for the Study of the Liver (EASL). Clinical practice guidance for rare metabolic liver diseases.

Coding Section

Code

Number

Description

HCPCS

J2840

Injection, sebelipase alfa, 1 mg: 1 billable unit = 1 mg

ICD-10

E75.5

Other lipid storage disorders

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each Policy. They may not be all-inclusive.

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

"Current Procedural Terminology © American Medical Association. All Rights Reserved" 

History From 2026 Forward

10/01/2026

New Policy

Complementary Content
${loading}